Differentiation of early-stage tumors from benign lesions manifesting as pure ground-glass nodule: a clinical prediction study based on AI-derived quantitative parameters

ObjectivesDifferentiating between benign and malignant pure ground-glass nodule (pGGN) is of great clinical significance. The aim of our study was to evaluate whether AI-derived quantitative parameters could predict benignity versus early-stage tumors manifesting as pGGN.MethodsA total of 1,538 pati...

Full description

Saved in:
Bibliographic Details
Main Authors: Shuxiang Chen, Huijuan Zhang, Yifan Chen, Shuo Chen, Wenfu Cao, Yongxiu Tong
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-05-01
Series:Frontiers in Oncology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2025.1573735/full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849735695017443328
author Shuxiang Chen
Huijuan Zhang
Yifan Chen
Shuo Chen
Wenfu Cao
Yongxiu Tong
author_facet Shuxiang Chen
Huijuan Zhang
Yifan Chen
Shuo Chen
Wenfu Cao
Yongxiu Tong
author_sort Shuxiang Chen
collection DOAJ
description ObjectivesDifferentiating between benign and malignant pure ground-glass nodule (pGGN) is of great clinical significance. The aim of our study was to evaluate whether AI-derived quantitative parameters could predict benignity versus early-stage tumors manifesting as pGGN.MethodsA total of 1,538 patients with pGGN detected by chest CT at different campuses of our hospital from May 2013 to December 2023 were retrospectively analyzed. This included CT and clinical data, as well as AI-derived quantitative parameters. All patients were randomly divided into a training group (n=893), an internal validation group (n=382), and an external validation group (n=263). Hazard factors for early-stage tumors were identified using univariate analysis and multivariate logistic regression analysis. Independent risk factors were then screened, and a prediction nomogram was constructed to maximize predictive efficacy and clinical application value. The performance of the nomogram was evaluated using ROC curves and calibration curves, while decision curve analysis (DCA) was used to assess the net benefit prediction threshold.ResultsThe final logistic model included nine independent predictors (age, location, minimum CT value, standard deviation, kurtosis, compactness, energy, costopleural distance, and volume) and was developed into a user-friendly nomogram. The AUCs of the ROC curves in the training, internal validation, and external validation cohorts were 0.696 (95% CI: 0.638–0.754), 0.627 (95% CI: 0.533–0.722), and 0.672 (95% CI: 0.543–0.801), respectively. The calibration plot demonstrated a good correlation between observed and predicted values, and the nomogram remained valid in the validation cohort. DCA showed that the model’s predictive performance was acceptable, providing substantial net benefit for clinical application.ConclusionsThe clinical prediction nomogram, based on AI-derived quantitative parameters, visually displays an overall score to differentiate benign lesions from early-stage tumors manifesting as pGGN. This nomogram may serve as a convenient screening tool for clinical use and provides a reference for formulating individualized follow-up and treatment plans for patients with pGGN.
format Article
id doaj-art-b1cbbb8276524892b2a71eca47ae10bc
institution DOAJ
issn 2234-943X
language English
publishDate 2025-05-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Oncology
spelling doaj-art-b1cbbb8276524892b2a71eca47ae10bc2025-08-20T03:07:28ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2025-05-011510.3389/fonc.2025.15737351573735Differentiation of early-stage tumors from benign lesions manifesting as pure ground-glass nodule: a clinical prediction study based on AI-derived quantitative parametersShuxiang ChenHuijuan ZhangYifan ChenShuo ChenWenfu CaoYongxiu TongObjectivesDifferentiating between benign and malignant pure ground-glass nodule (pGGN) is of great clinical significance. The aim of our study was to evaluate whether AI-derived quantitative parameters could predict benignity versus early-stage tumors manifesting as pGGN.MethodsA total of 1,538 patients with pGGN detected by chest CT at different campuses of our hospital from May 2013 to December 2023 were retrospectively analyzed. This included CT and clinical data, as well as AI-derived quantitative parameters. All patients were randomly divided into a training group (n=893), an internal validation group (n=382), and an external validation group (n=263). Hazard factors for early-stage tumors were identified using univariate analysis and multivariate logistic regression analysis. Independent risk factors were then screened, and a prediction nomogram was constructed to maximize predictive efficacy and clinical application value. The performance of the nomogram was evaluated using ROC curves and calibration curves, while decision curve analysis (DCA) was used to assess the net benefit prediction threshold.ResultsThe final logistic model included nine independent predictors (age, location, minimum CT value, standard deviation, kurtosis, compactness, energy, costopleural distance, and volume) and was developed into a user-friendly nomogram. The AUCs of the ROC curves in the training, internal validation, and external validation cohorts were 0.696 (95% CI: 0.638–0.754), 0.627 (95% CI: 0.533–0.722), and 0.672 (95% CI: 0.543–0.801), respectively. The calibration plot demonstrated a good correlation between observed and predicted values, and the nomogram remained valid in the validation cohort. DCA showed that the model’s predictive performance was acceptable, providing substantial net benefit for clinical application.ConclusionsThe clinical prediction nomogram, based on AI-derived quantitative parameters, visually displays an overall score to differentiate benign lesions from early-stage tumors manifesting as pGGN. This nomogram may serve as a convenient screening tool for clinical use and provides a reference for formulating individualized follow-up and treatment plans for patients with pGGN.https://www.frontiersin.org/articles/10.3389/fonc.2025.1573735/fulllungpure ground-glass noduleidentificationnomogramCTAI
spellingShingle Shuxiang Chen
Huijuan Zhang
Yifan Chen
Shuo Chen
Wenfu Cao
Yongxiu Tong
Differentiation of early-stage tumors from benign lesions manifesting as pure ground-glass nodule: a clinical prediction study based on AI-derived quantitative parameters
Frontiers in Oncology
lung
pure ground-glass nodule
identification
nomogram
CT
AI
title Differentiation of early-stage tumors from benign lesions manifesting as pure ground-glass nodule: a clinical prediction study based on AI-derived quantitative parameters
title_full Differentiation of early-stage tumors from benign lesions manifesting as pure ground-glass nodule: a clinical prediction study based on AI-derived quantitative parameters
title_fullStr Differentiation of early-stage tumors from benign lesions manifesting as pure ground-glass nodule: a clinical prediction study based on AI-derived quantitative parameters
title_full_unstemmed Differentiation of early-stage tumors from benign lesions manifesting as pure ground-glass nodule: a clinical prediction study based on AI-derived quantitative parameters
title_short Differentiation of early-stage tumors from benign lesions manifesting as pure ground-glass nodule: a clinical prediction study based on AI-derived quantitative parameters
title_sort differentiation of early stage tumors from benign lesions manifesting as pure ground glass nodule a clinical prediction study based on ai derived quantitative parameters
topic lung
pure ground-glass nodule
identification
nomogram
CT
AI
url https://www.frontiersin.org/articles/10.3389/fonc.2025.1573735/full
work_keys_str_mv AT shuxiangchen differentiationofearlystagetumorsfrombenignlesionsmanifestingaspuregroundglassnoduleaclinicalpredictionstudybasedonaiderivedquantitativeparameters
AT huijuanzhang differentiationofearlystagetumorsfrombenignlesionsmanifestingaspuregroundglassnoduleaclinicalpredictionstudybasedonaiderivedquantitativeparameters
AT yifanchen differentiationofearlystagetumorsfrombenignlesionsmanifestingaspuregroundglassnoduleaclinicalpredictionstudybasedonaiderivedquantitativeparameters
AT shuochen differentiationofearlystagetumorsfrombenignlesionsmanifestingaspuregroundglassnoduleaclinicalpredictionstudybasedonaiderivedquantitativeparameters
AT wenfucao differentiationofearlystagetumorsfrombenignlesionsmanifestingaspuregroundglassnoduleaclinicalpredictionstudybasedonaiderivedquantitativeparameters
AT yongxiutong differentiationofearlystagetumorsfrombenignlesionsmanifestingaspuregroundglassnoduleaclinicalpredictionstudybasedonaiderivedquantitativeparameters